The long-term clinical course and results of biopsies in 21 patients studied with monoclonal antimyosin antibodies more than 12 months after heart transplantation according to the presence and degree of antimyosin-antibody uptake is described. Eighteen men and three women aged 20-52 years (39+±9 years) were studied with antimyosin antibodies 12-40 months (mean, 22+±9 months) after heart transplantation, and followed for a mean of 18 months (10-28 months). The number of biopsies performed during follow-up was 102. Results showed normal antimyosin-antibody studies in nine patients and abnormal studies in 12 patients. Myocyte damage was identified in 18 of the 102 biopsies (17.6%), one in the normal antimyosin-antibody group of patients and 17 in those patients with myocardial antimyosinantibody uptake. Patients who developed rejection comprised 11% and 67% of each respective group; the mean number of rejection episodes per patient was 0.11±0.33 and 1.41±+1.41, respectively (p<0.01). A trend was noted by which higher heart-to-lung ratios were associated with greater probability of rejection. Conclusively, 1) antimyosin-antibody studies performed after more than 1 year after heart transplantation indicate the presence and level of rejection activity, 2) groups of patients at risk for developing rejection at biopsy during long-term follow-up may be detected by antimyosin-antibody study, and 3) surveillance for rejection and the degree of immunosuppression should be tailored to meet individual patient needs. (Circulation 1990;82:2100-2108 M onoclonal antimyosin antibodies labeled with indium-111 allow in vivo noninvasive detection of myocardial damage. Binding of these antibodies to intracellular myosin takes place only when sarcolemmal disruption occurs and the cell is irreversibly damaged.1-4This technique has been useful in the diagnosis of acute myocardial infarction5 and acute myocarditis,6 and the detection of active myocyte damage in chronic dilated cardiomyopathy.7 After heart transplantation, antimyosin studies have been used to detect rejection89 where conventional diagnostic criteria is based on the morphological identification of myocyte damage at endomyocardial biopsy.10 We have recently developed a means to quantify the relative myocardial uptake of`ttIn-monoclonal antimyosin antibodies in humans through a heart-tolung ratio,1' and have shown that after heart transplantation, sequential studies performed in individual patients provide an insight into the level and changes in rejection activity.9 Shortly after transplantation, high antimyosin uptake is invariably detected, and a gradual reduction in the degree of uptake in subsequent months is seen. After the first year, one group of patients show a normal antimyosin study, whereas persistent myocardial uptake is seen in others. No information on the long-term significance of antimyosin studies performed at this time after surgery is available. The present report provides the first description of the significance of antimyosin studies performed after the first year after transplantation in terms of the probability for developing subsequent rejection at biopsy during long-term follow-up.
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We have recently developed a means to quantify the relative myocardial uptake of`ttIn-monoclonal antimyosin antibodies in humans through a heart-tolung ratio,1' and have shown that after heart transplantation, sequential studies performed in individual patients provide an insight into the level and changes in rejection activity.9 Shortly after transplantation, high antimyosin uptake is invariably detected, and a gradual reduction in the degree of uptake in subsequent months is seen. After the first year, one group of patients show a normal antimyosin study, whereas persistent myocardial uptake is seen in others. No information on the long-term significance of antimyosin studies performed at this time after surgery is available. The present report provides the first description of the significance of antimyosin studies performed after the first year after transplantation in terms of the probability for developing subsequent rejection at biopsy during long-term follow-up.
Methods
Only those patients who had received an orthotopic heart transplantation at least 1 year before the antimyosin study were included. Time elapsed from transplantation to antimyosin study ranged from 12 to 40 months (22±9 months). There were 21 patients, 18 men and three women, aged 20-52 years (39±9 years). Follow-up after antimyosin extended from 10 to 28 months (18±5 months). The total number of biopsies performed during this interval was 102, that is, three to eight (4.8±1.6) biopsies per patient.
Immunosuppression and Management of Rejection
Immediately after transplantation, immunosuppression consisted of the administration of cyclosporine and steroids. Equine antithymocytic globulin (ATGAM) was given for 10 days after transplantation. Cyclosporine doses were adjusted to whole blood levels of 400-800 ng/ml. Steroids were given in the form of a bolus of methylprednisolone, 1 g, 500 mg, and 500 mg for the first 3 days, followed by 1 mg/kg/day of prednisone and reduction to 0.2 mg/ kg/day. Endomyocardial biopsies were performed weekly during the first month, every 15 days to the first 3 months, monthly until 6 months, and every 3 months until the first year.12 After the first year after the transplantation, biopsies were performed every 4 months; three to five samples were taken in each procedure. Azathioprine was given to two patients at a dose of 3-5 mg/day to attain a total leukocyte blood count of 3,000-5,000 mm3.
Diagnosis of rejection was made by interpretation of endomyocardial biopsies according to Billingham's diagnostic criteria.10 For the purpose of the present study, the term rejection episode was equated with a biopsy showing myocyte damage (moderate to severe rejection). Treatment was given whenever myocyte damage was detected, but not when round cell infiltration (mild rejection) was the sole finding, and consisted in a 3-day course of an intravenous bolus of methylprednisolone (1 g, 500 mg, and 500 mg) and antithymocytic globulin (5 mg/kg/day and further adjustment to a T-cell level of 100-200 mm3). Control biopsies performed after a rejection episode were excluded from the analysis. Surveillance for vascular rejection was undertaken every 4 months through exercise TI-201 studies and yearly with coronary angiography. We have recently described that when detected at early stages, reversal of small-or medium-sized coronary vessel obstruction with medical treatment is possible.13 When a positive Tl-201 study developed and pruning of the small-and medium-sized coronary vessels was detected, treatment was started with a high-dose bolus of methylprednisolone and antithymocytic globulin.
Left ventricular function was studied at the end of follow-up by means of M-mode and two-dimensional echocardiography.
Antimyosin Studies
Antimyosin administration was made to coincide with endomyocardial biopsies. The Fab fragments of R11D10-Fab-diethylenetriamine pentaacetic acid (R11D10-Fab-DTPA) monoclonal antimyosin antibodies (Centocor) were prepared in individual doses to which 2 mCi of "1In-chloride was added to produce a 90% labeling efficacy at room temperature. Patients were injected intradermally with 0.1 ml of the labeled antibody to test for hypersensitivity. If no weal was observed, a dose of 0.5 mg of R11D10-Fab-DPTA labeled with 2.0 mCi of`11In was administered intravenously. All patients presented a negative intradermal test at 30 minutes. Planar scintigraphic images were obtained at 48 hours after antimyosin administration. Imaging was performed in anterior projection by using a conventional large field-of-view camera with a high-resolution medium-energy collimator and 20% window centered on 247 and 173 KeV peaks. A minimum of 500,000 counts between 5 and 10 minutes were collected. Analog and digital images collected in a 128 x 128 matrix were stored for subsequent analysis.
To quantify the degree of uptake, an experienced observer, unaware of the clinical or biopsy results, calculated an index by dividing average counts per pixel in a cardiac region of interest by those obtained in a pulmonary region of interest." The quantitative criterion for normality was set to a heart-to-lung ratio of 1.55, calculated on the basis of the mean plus two standard deviations of that obtained in a normal population.1' To maximize the difference between the high and low antimyosin uptake groups, the cutoff point between different degrees of positive antimyosin studies in patients with heart transplantation (low-and high-uptake groups) was arbitrarily set at 1.75, after visual inspection of a plot between the number of rejection episodes per patient detected during follow-up and the heart-to-lung ratios.
Statistical Analysis
The Kolmogorov test was used to check for normal distribution of antimyosin ratio and rejection episodes during the study period. Results suggested that nonparametric tests should be used (Kruskal-Wallis one-way analysis of variance and Mann-Whitney U Wilcoxon sum W test).
A comparison was undertaken between the rejection activity detected during the study with that obtained in the same patients during their first year after transplantation. To allow comparison between these two different intervals, the percentage of positive biopsies detected in each period was normalized by the number of months of the corresponding interval. Thus, the following two variables were calculated: P1 is the biopsies showing rejection divided by the number of biopsies during the first year divided and by the product of 12 and 100 (percentage of positive biopsies per month during the first year), and P2 is the positive biopsies divided by the number To evaluate if the degree of antimyosin uptake was associated with a greater probability of biopsy-proven rejection during follow-up, patients were grouped according to those with a normal (nine patients), low (seven patients), and high (five patients) heart-to- lung ratio. The groups of patients had similar ages, times elapsed from transplantation, months of follow-up, and numbers of biopsies performed. During follow-up, a trend was noted in which the percentage of patients who rejected, the mean number of rejection episodes per patient during the study, and the total number of rejection episodes since transplantation increased according to both the presence and degree of antimyosin uptake ( Figure 2 , Table 3 ). One patient in the group with high antimyosin uptake, with a heart-to-lung ratio greater than 2.00, developed vascular rejection that was successfully managed with medical treatment.
Development of Tolerance to Graft and Antimyosin Uptake
The mean number of rejection episodes detected by biopsy during the study in the 21 patients was 0.86±+1.28 (range, 0-5). These same patients had suffered a mean of 2.52+1.89 (range, 0-8) rejection episodes during their first year after heart transplantation (p<0.001). The percentage of positive biopsies per month was also lower during the study period (P2) when compared with the first year after heart transplantation (P1), that is, 0.65+±0.99 versus 1.62+1.21, respectively (p<0.001). These data are ANTIMYOSIN RATIO
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consistent with the well-known reduction in rejection activity after transplantation. The percentage of reduction in rejection activity between both intervals, however, was different in the patients in the two antimyosin groups (Table 4) . During the first year after transplantation, rejection activity had been significantly increased in the patients in the abnormal antimyosin group as compared with the patients in the normal group, or 3.4±+1.7 versus 1.3±+1.3 rejection episodes per patient (p<0.01) and 2.19±1.14% versus 0.85+±0.85% rejection episodes per biopsy per month (p<0.01). The percentage of reduction of rejection episodes between the first year after heart transplantation and the study period was 57+40% in the patients in the abnormal antimyosin group and 95 ± 10% in the patients in the normal antimyosin group (p<0.03). Thus, development of tolerance to the graft had been quicker in those patients who showed a normal antimyosin study than in those patients in whom myocardial uptake of antimyosin had been detected. When groups of patients were divided according to both the presence and degree of antimyosin uptake (Table 5 ), it was shown that tolerance to the graft was quicker in the patients in the normal group, but no differences were detected between the patients in the low and high antimyosin uptake groups.
Discussion
During the first few months after heart transplantation, patients invariably show myocardial uptake of monoclonal antimyosin antibody, revealing the presence of active myocardial damage. During the first year, a gradual decrease in myocardial uptake is observed that is paralleled by a progressive reduction in the number of rejection episodes at biopsy. After the first year, some patients show normal antimyosin studies, whereas in other patients, persistent myocardial uptake of antimyosin is detected.9 The present report reveals that at this time after transplantation, rejection was seldom detected during follow-up in patients with normal antimyosin studies, whereas rejection episodes were observed in 67% of those patients with abnormal scans. Furthermore, a trend was noted in which increasing degrees of antimyosin uptake correlated with a higher probability of detecting rejection at biopsy during follow-up. Antimyosin studies also reflected the total number of rejection episodes since transplantation.
The number of rejection episodes per patient detected at biopsy was greater during the first year after transplantation than during the study interval (which started an average of 22 months after the surgery). This is in agreement with the long-term reduction of rejection activity after transplantation (i.e., the so-called development of tolerance to the graft).14 This reduction took place in patients with both normal and abnormal antimyosin studies; however, the percentage of reduction of rejection episodes between the two intervals was significantly greater in the patients with normal antimyosin studies. Thus, development of tolerance to the graft was quicker in patients with a normal antimyosin study than in those who had myocardial antimyosin uptake.
These results indicate that tolerance varies from patient to patient, and that this is reflected on antimyosin studies performed after 1 year after heart transplantation. Therefore, in monoclonal antimyosin studies performed after the first year after heart transplantation, HLR, heart-to-lung ratio; NS, not significant; P1, number of positive biopsies for rejection/number of biopsies performed during the first year/12; P2, number of positive biopsies for rejection/number of biopsies performed during follow-up in the present study/number of months of follow-up (see text). *One-way analysis of variance with multiple range test using Tukey-HSD procedure. tReduction in the percentage of positive biopsies performed during the first year after transplantation compared with those detected during the study interval, (P,-P2)/P1.100. 57+37 NS NL, patients with normal antimyosin uptake; HI. patients with high antimyosin uptake; LO, patients with low antimyosin uptake; NS, not significant; P1, number of positive biopsies for rejection per number of biopsies performed during the first year/12; P2, number of positive biopsies for rejection/number of biopsies performed during follow-up in the present study/number of months of follow-up (see text).
*One-way analysis of variance with multiple range test using Tukey-HSD procedure. tReduction in the percentage of positive biopsies performed during the first year after transplantation compared with those detected during the study interval, (PI-P,)/P1.100.
the presence and probably the degree of antimyosin uptake provide a noninvasive indicator of the rejection activity in individual patients.
Significance of Positive Antimyosin Studies in Presence of Negative Endomyocardial Biopsies
The discrepancy between the positivity of antimyosin studies in the absence of myocyte damage at endomyocardial biopsy has been described both in cardiac rejection after heart transplantation and in other types of diffuse myocardial damage,6-9 but its significance is not clearly understood. In patients with heart transplantation, Frist and colleagues8 found two patients with negative biopsies and positive scans; in a recent publication, we reported the results of 53 antimyosin studies in patients with heart transplantation, in whom 15 positive antimyosin scans coincided with negative biopsies. 9 Yasuda and coworkers,6 in a series of 28 patients with acute myocarditis, found eight patients with a positive antimyosin study who did not show myocarditis at biopsy. In a recent paper, we have described such a discrepancy in 16 of 17 patients with chronic idiopathic stable dilated cardiomyopathy. 7 The cause of such discrepancy remains unanswered. In this respect, heart transplantation provides a unique human model to adequately interpret such findings. In the present study, long-term follow-up of eight such patients revealed biopsy-proven rejection episodes in four. This fact probably indicates the presence of a sampling error of endomyocardial biopsy in the detection of rejection-induced cell damage after transplantation. This is not surprising because, in rejection as in myocarditis, the distribution of myocardial cell damage is patchy, which indicates that imaging with monoclonal antimyosin antibodies probably constitutes a more sensitive technique than interpretation of myocardial samples taken at endomyocardial biopsy in the detection of rejection-induced myocyte damage. other patients who show persistent myocardial uptake, such a treatment might be inadequate. In the group of patients with an adequate level of suppression, and probably after the first year of transplantation, noninvasive follow-up could be considered. Unpublished observations in our laboratory while performing repeat studies in these patients indicate that a steady state of tolerance is kept during longterm follow-up (Figure 3 ). In such patients, biopsies can be avoided and surveillance of rejection with antimyosin studies can be done at longer intervals ( Figure 4 ). This approach could be especially useful in children with heart transplantation.
Patients with myocardial uptake of antimyosin after the first year pose a different problem. The 
